RT Journal Article
SR Electronic
T1 Systematic examination of T cell responses to SARS-CoV-2 versus influenza virus reveals distinct inflammatory profile
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.27.20183319
DO 10.1101/2020.08.27.20183319
A1 Law, Jaclyn C.
A1 Koh, Wan Hon
A1 Budylowski, Patrick
A1 Lin, Jonah
A1 Yue, FengYun
A1 Abe, Kento T.
A1 Rathod, Bhavisha
A1 Girard, Melanie
A1 Li, Zhijie
A1 Rini, James M.
A1 Mubareka, Samira
A1 McGeer, Allison
A1 Chan, Adrienne K.
A1 Gingras, Anne-Claude
A1 Watts, Tania H.
A1 Ostrowski, Mario
YR 2020
UL http://medrxiv.org/content/early/2020/09/01/2020.08.27.20183319.abstract
AB There is a pressing need for an in-depth understanding of immunity to SARS-CoV-2. Here we investigated T cell recall responses to fully glycosylated Spike trimer, recombinant N protein as well as to S, N, M and E peptide pools in the early convalescent phase. All subjects showed SARS-CoV-2-specific T cell responses to at least one antigen. SARS-CoV-2-specific CD4+ T cells were primarily of the central memory phenotype and exhibited a lower IFN-γ to TNF-α ratio compared to influenza-specific responses of the same donors, independent of disease severity. SARS-CoV-2-specific T cells were less multifunctional than influenza-specific T cells, particularly in severe cases, potentially suggesting exhaustion. High IL-10 production was noted in response to N protein, possibly contributing to immunosuppression, with potential implications for vaccine design. We observed granzyme B+/IFN-γg+ CD4+ and CD8+ proliferative responses to peptide pools in most individuals, with CD4+ responses predominating over CD8+ responses. Peripheral T follicular helper responses to S or N strongly correlated with serum neutralization assays as well as RBD-specific IgA. Overall, T cell responses to SARS-CoV-2 are robust, however, CD4+ Th1 responses predominate over CD8+ responses and are more inflammatory with a weaker Tfh response than influenza-specific CD4+ responses, potentially contributing to COVID-19 disease.Competing Interest StatementQuestCap provided funds to the ACG and SM labs for development of assays used in this project. All other authors have no conflicts of interest to declare.Funding StatementThis research was funded by a FAST grant from the Thistledown foundation (to T.H.W.) and by a grant VR1-172711 from the Canadian Institutes of Health research to T.H.W., M.O. and A.C.G. M.O. receives funding from the Ontario HIV Treatment Network (OHTN), the Li Ka Shing Knowledge Institute, and the Juan and Stefania fund for COVID-19 and other virus infections. Funding for the development of the assays in the Gingras lab was provided through generous donations from the Royal Bank of Canada (RBC), QuestCap and the Krembil Foundation to the Sinai Health System Foundation; the equipment used is housed in the Network Biology Collaborative Centre at the Lunenfeld-Tanenbaum Research Institute, a facility supported by Canada Foundation for Innovation funding, by the Ontarian Government and by Genome Canada and Ontario Genomics (OGI-139). JCL and KTA were recipients of Ontario Graduate Scholarships.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The human subjects research in this manuscript was approved by St. Michael's Hospital REB20-044c to MO. Additional healthy donors were recruited at the University of Toronto (REB# 00027673 to THW). All human subjects research was done in compliance with the Declaration of Helsinki.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data will be made available by the authors upon request, once paper has undergone full peer review and acceptance.